Literature DB >> 9622060

Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer.

M Bouvet1, L M Ellis, M Nishizaki, T Fujiwara, W Liu, C D Bucana, B Fang, J J Lee, J A Roth.   

Abstract

Recent studies have indicated that angiogenesis may be regulated, in part, by p53 tumor suppressor gene function. We hypothesized that wild-type p53 replacement would down-regulate vascular endothelial growth factor (VEGF) expression and inhibit angiogenesis. KM12L4 and SW620, human colon cancer cell lines with p53 mutations, were transduced with a replication-defective adenoviral vector containing the wild-type p53 gene (Ad5/CMV/p53). Reverse transcription-PCR confirmed the presence of p53 in Ad5/CMV/p53-transduced cells. Transduction of colon cancer cells with wild-type p53 decreased VEGF RNA expression compared with that of controls. The decrease in VEGF expression in SW620 cells was dose dependent, with a 49% decrease observed at a multiplicity of infection of 50, and a 71% decrease observed at a multiplicity of infection of 100. Similar effects were seen in KM12L4 cells. VEGF supernatant protein levels were significantly reduced compared with those in nontransduced controls 48 h after the introduction of wild-type p53. Ad5/CMV/p53 inhibited tumor cell-induced angiogenesis in vivo. Restoration of wild-type p53 expression may decrease tumor growth by inhibiting the angiogenic response. These findings may explain, in part, the bystander effect seen with p53 tumor suppressor gene therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622060

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  44 in total

1.  Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; P E Thorpe; R A Brekken; S Konstantinos; G Fountzilas; K C Gatter; A L Harris
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha.

Authors:  R Ravi; B Mookerjee; Z M Bhujwalla; C H Sutter; D Artemov; Q Zeng; L E Dillehay; A Madan; G L Semenza; A Bedi
Journal:  Genes Dev       Date:  2000-01-01       Impact factor: 11.361

3.  Overcoming resistance to anti-PD immunotherapy in a syngeneic mouse lung cancer model using locoregional virotherapy.

Authors:  Xiang Yan; Li Wang; Ran Zhang; Xingxiang Pu; Shuhong Wu; Lili Yu; Ismail M Meraz; Xiaoshan Zhang; Jacqueline F Wang; Don L Gibbons; Reza J Mehran; Stephen G Swisher; Jack A Roth; Bingliang Fang
Journal:  Oncoimmunology       Date:  2017-10-31       Impact factor: 8.110

4.  Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.

Authors:  Lyudmila Burdelya; Maciej Kujawski; Guilian Niu; Bin Zhong; Tianhong Wang; Shumin Zhang; Marcin Kortylewski; Kenneth Shain; Heidi Kay; Julie Djeu; William Dalton; Drew Pardoll; Sheng Wei; Hua Yu
Journal:  J Immunol       Date:  2005-04-01       Impact factor: 5.422

5.  VEGF expression and its reguration by p53 gene transfection in endometrial carcinoma cells.

Authors:  T Fujisawa; J Watanabe; Y Kamata; M Hamano; H Hata; H Kuramoto
Journal:  Hum Cell       Date:  2003-03       Impact factor: 4.174

Review 6.  Clinical significance of angiogenesis in gastrointestinal cancers: a target for novel prognostic and therapeutic approaches.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; John Wong
Journal:  Ann Surg       Date:  2003-07       Impact factor: 12.969

Review 7.  p53 gene therapy for esophageal cancer.

Authors:  Hideaki Shimada; Hisahiro Matsubara; Takenori Ochiai
Journal:  J Gastroenterol       Date:  2002-11       Impact factor: 7.527

8.  In vivo recombinant adenovirus-mediated p53 gene therapy in a syngeneic rat model for colorectal cancer.

Authors:  Jeong-Heum Baek; Munna L Agarwal; Raymond R Tubbs; Alex Vladisavljevic; Hiroshi Tomita; Ronald M Bukowski; Jeffrey W Milsom; Jin-Man Kim; Jin-Young Kwak
Journal:  J Korean Med Sci       Date:  2004-12       Impact factor: 2.153

9.  Tumour angiogenesis as a prognostic factor for disease dissemination in retinoblastoma.

Authors:  E Ferrari Marback; V E A Arias; A Paranhos; F A Soares; A L Murphree; C M Erwenne
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

Review 10.  The role of antiangiogenesis therapy: bevacizumab and beyond.

Authors:  Hernán Cortés-Funes
Journal:  Clin Transl Oncol       Date:  2009-06       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.